ArticleBrain communications2020
In the blood: biomarkers for amyloid pathology and neurodegeneration in Alzheimer's disease.
Article in Brain communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Brain-Derived Exosomal Proteins as Effective Biomarkers for Alzheimer's Disease: A Systematic Review and Meta-Analysis.Biomolecules · 2021Pooled it
- A six-year risk assessment for dementia and Alzheimer's disease in the general population through immunoprecipitation-mass spectrometry plasma amyloid quantification.The journal of prevention of Alzheimer's disease · 2025Article
- Circulating Biomarkers for the Early Diagnosis of Alzheimer's Disease.International journal of molecular sciences · 2025Review
- Biomarkers of Neurodegenerative Diseases: Biology, Taxonomy, Clinical Relevance, and Current Research Status.Biomedicines · 2022Review
- Antimicrobial Peptides (AMPs) in the Pathogenesis of Alzheimer's Disease: Implications for Diagnosis and Treatment.Antibiotics (Basel, Switzerland) · 2022Review
- Detection, Diagnosis and Treatment of Acute Ischemic Stroke: Current and Future Perspectives.Frontiers in medical technology · 2022Review
- Tau kinetics in Alzheimer's disease.Frontiers in aging neuroscience · 2022Article
- Post-Stroke Cognitive Impairment: Pathophysiological Insights into Brain Disconnectome from Advanced Neuroimaging Analysis Techniques.Journal of stroke · 2021Review
- T2 heterogeneity as an in vivo marker of microstructural integrity in medial temporal lobe subfields in ageing and mild cognitive impairment.NeuroImage · 2021Article
- Nanoparticle-Enabled Enrichment of Longitudinal Blood Proteomic Fingerprints in Alzheimer's Disease.ACS nano · 2021Article
- Novel Trends in Electrochemical Biosensors for Early Diagnosis of Alzheimer's Disease.International journal of analytical chemistry · 2021Review
- The application of optical coherence tomography angiography in Alzheimer's disease: A systematic review.Alzheimer's & dementia (Amsterdam, Netherlands) · 2021Review
- Biosensors-on-Chip: An Up-to-Date Review.Molecules (Basel, Switzerland) · 2020Review
- Body Fluid Biomarkers for Alzheimer's Disease-An Up-To-Date Overview.Biomedicines · 2020Review
- Association of plasma biomarkers with cognitive function in persons with dementia and cognitively healthy in the Democratic Republic of Congo.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
- Comment on
- Comment on
Authors and funding
2 authors.
Funding
Abstract
This scientific commentary refers to 'Plasma total-tau, neurofilament light chain and amyloid-β levels and risk of dementia: a population-based study' by de Wolf
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.